Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (DE:37Z)
FRANKFURT:37Z
Holding DE:37Z?
Track your performance easily
37Z Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.48 - €2.92
Previous Close€1.22
Volume0.00
Average Volume (3M)2.39K
Market Cap
€102.79M
Enterprise Value€48.51M
Total Cash (Recent Filing)$92.72M
Total Debt (Recent Filing)$35.71M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Mar 04, 2025EPS Estimate
-€0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding89,343,634
10 Day Avg. Volume189
30 Day Avg. Volume2,386
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
€3.86Price Target Upside217.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Allakos News
PremiumCompany Announcements
Allakos Reports Q3 2024 Results and Research Progress
PremiumCompany Announcements
Allakos Inc. Alters Lease Agreement for Cost Savings
PremiumCompany Announcements
Allakos Progress Update on AK006 and Future Milestones
Bulls Say, Bears Say
Bulls Say
Clinical DataEnthusiasm for AK006 is expected to build as incremental clinical data is gathered, with key data from CSU patients providing a major catalyst for ALKK shares.
Receptor OccupancyPhase 1 data confirmed AK006 reaches the pathogenic cell type (mast cells) in the target tissue (skin) with receptor occupancy levels (>90%) that exceed levels associated with potent inhibition in preclinical models (~70%).
Safety And EfficacyThe safety profile of subcutaneous AK006 up to 720mg appeared safe and well-tolerated with no serious adverse events or dose-limiting toxicities.
Bears Say
Clinical DataThe lack of pharmacodynamic data was the likely cause for ALLK trading down following this update.
Data AvailabilityNot enough sample for ex-vivo mast cell pharmacodynamic analysis suggests challenges in data collection.
Market ConfidenceStrong proof-of-concept data is seen as key to restoring confidence in ALLK's CSU development program, following the recent clinical setbacks for lirentelimab in atopic dermatitis and CSU.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.23% Insiders
10.68% Mutual Funds
50.58% Other Institutional Investors
24.99% Public Companies and
Individual Investors
37Z FAQ
What was Allakos Inc’s price range in the past 12 months?
Allakos Inc lowest stock price was €0.48 and its highest was €2.92 in the past 12 months.
What is Allakos Inc’s market cap?
Currently, no data Available
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is Mar 04, 2025 which is in 72 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on Nov 06, 2024. The company reported -€0.2 earnings per share for the quarter, beating the consensus estimate of -€0.236 by €0.036.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -€0.16.
How many shares outstanding does Allakos Inc have?
Allakos Inc has 89,343,636 shares outstanding.
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of -€0.2 in its last earnings report, beating expectations of -€0.236. Following the earnings report the stock price went up 2.468%.
Which hedge fund is a major shareholder of Allakos Inc?
Among the largest hedge funds holding Allakos Inc’s share is Platinum Investment Management. It holds Allakos Inc’s shares valued at 692K.
---
Allakos Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.86 (217.13% Upside)
€3.86 (217.13% Upside)
Blogger Sentiment
Bearish
DE:37Z Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-54.54%
12-Months-Change
Fundamentals
Return on Equity
-121.68%
Trailing 12-Months
Asset Growth
-56.11%
Trailing 12-Months
Company Description
Allakos Inc
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
37Z Stock 12 Month Forecast
Average Price Target
€3.86
▲(217.13% Upside)
Technical Analysis
Allakos
―
Adaptimmune Therapeutics
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Fate Therapeutics
―
Best Analysts Covering 37Z
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+11.26%
reiterated a buy rating 5 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +11.26% per trade.
---